Insula Badania Sp. z o.o.
- Address
- Ul. Klobucka 23c/109, 02-699 Warsaw, Poland
Nervous System Diseases
The research team at Insula Badania Sp. z o.o. is dedicated to advancing therapies for Parkinson disease, with a focus on early and genetic forms of the condition.
- Early Parkinson disease
- Idiopathic Parkinson disease
- LRRK2‑driven Parkinson disease
- Safety and efficacy assessment of investigational agents
- Biomarker‑guided clinical evaluation
Ongoing studies aim to determine whether novel compounds can safely modify disease progression and improve motor function in patients.
Mental Disorders
Investigations at the Warsaw clinic address neuropsychiatric complications of dementia, specifically Alzheimer’s disease psychosis.
- Hallucinations and delusions associated with Alzheimer’s disease
- Long‑term safety and tolerability of new treatments
- Adult participants with dementia‑related psychosis
- Open‑label study designs for real‑world assessment
- Improving quality of life for patients and caregivers
The goal is to evaluate whether emerging therapies can reduce psychotic symptoms while maintaining overall safety for this vulnerable population.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Maplight Therapeutics Inc.1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Insula Badania Sp. z o.o.
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of NEU-411 Maleate in LRRK2-Driven Early Parkinson's Disease: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial | Neuron23 Inc. | Phase II | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 5-[(1R,5R)-3-AZABICYCLO[3.1.0]HEXAN-1-YL]-3-METHYL-1,2,4-OXADIAZOLE | 1 | Unknown | 2026-07-03 | 2026-07-03 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.